AANS
April 13-17, 2019
San Diego Convention Center
San Diego, CA

 

NXDC Booth 2239 in Exhibit Halls D-H

If you are interested in meeting with us at AANS or finding out more about Gleolan, please fill out the form below.

Visit us at AANS 2019!

American Association of Neurological Surgeons

LUNCH AND LEARN

Practical Applications of
Fluorescence-Guided Surgery

An approximately 30-minute speaking program with hospital-provided video clips and concluded with a 10-minute Q&A.


AANS Learning Center
Booth #340, Hall D
Sunday, April 14th
11:40a-12:25p




Speakers Include:

Steven Kalkanis, MD
&
Nader Sanai, MD 
Steven N. Kalkanis, MD
Dr. Kalkanis is professor and chair of the Department of Neurosurgery, and co-director of the Neuroscience Institute at Henry Ford Health System in Detroit, Michigan, where he also serves as Medical Director of the Henry Ford Cancer Institute (HFCI). The newly formed HFCI, under the leadership of Dr. Kalkanis, has grown to a $1.2 billion enterprise with 1425 employees treating more than 8,000 new cancer patients and over 100,000 patient visits each year across all five Henry Ford sites – one of the largest cancer centers in the country. Dr. Kalkanis and his team also spearheaded one of the country’s most comprehensive precision medicine and molecular tumor board programs for all cancer types.
 
Nader Sanai, MD
Nader Sanai, MD, is a neurosurgical oncologist who has been internationally recognized for his clinical expertise and research efforts dedicated to the treatment of brain tumors. Dr. Sanai’s clinical practice is devoted entirely to patients with tumors of the brain and spine, including those in high-risk areas. He also has extensive experience using intraoperative mapping to maximize tumor removal while preserving crucial structures controlling motor and language function. Gliomas, meningiomas, metastatic tumors, and complex tumors of the skull base are just some of the tumor types he routinely treats using both operative and radiosurgery techniques.
 
GleolanTM (aminolevulinic acid HCl) is the first and only FDA approved optical imaging agent for use during fluorescence-guided surgery (FGS) in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery.
 

All Rights Reserved 2019

Important Safety Information

Contraindications
 
Do not use Gleolan in patients with:
Warnings and Precautions  
Due to the risk of phototoxic reactions, do not administer phototoxic drugs and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.
 
Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma,
including false negatives and false positives. Non-fluorescing tissue in the surgical field does not
rule out the presence of tumor in patients with glioma. Fluorescence may be seen in areas of inflammation or metastases from other tumor types.
 
Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these
reactions include anaphylactic shock, swelling, and urticaria. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.
 
Adverse Reactions
Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting.
 
Nervous system disorders occurred in 29% of patients within the first week after surgery and events occurring in >1% of patients included: aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in <1% of patients in the first 6 weeks after surgery.  In a randomized clinical trial, the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to ALA fluorescence arm compared to the control arm. An imbalance was notable for the adverse events aphasia, ataxia, convulsion and hemianopsia and is likely related to the higher amount of brain resection performed in the ALA arm.  At longer follow up periods, the numbers between the two arms appeared similar. 
 
Worsening of >2 Common Toxicity Criteria grades in alanine aminotransferase and gamma-glutamyl transferase occurred in 15.8% and 11.6% of patients, respectively, within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal for each parameter. At 6 weeks, these measurements remained elevated in 2.9% and 7.5% of patients, respectively. There were no cases of liver failure.
 
Drug-Drug Interactions
See information under Warnings and Precautions regarding phototoxic reactions.


Please see Full Prescribing Information